Patient-Derived Xenograft / PDX Model Market by Type (Mice, Rat), Implantation Method (Subcutaneous, Orthotopic), Tumor Type (Respiratory, Hematological), Application (Drug Development, Biobanks), End User (Pharma, Biotech, CROs) - Global Forecast to 2028

Patient-Derived Xenograft / PDX Model Market by Type (Mice, Rat), Implantation Method (Subcutaneous, Orthotopic), Tumor Type (Respiratory, Hematological), Application (Drug Development, Biobanks), End User (Pharma, Biotech, CROs) - Global Forecast to 2028



The patient-derived xenografts/ PDX model market is projected to reach USD 687 million by 2028 from USD 366 million in 2023, at a CAGR of 13.4% during the forecast period. The key factors driving the growth of the global patient-derived xenograft/ PDX model market are the enhanced preclinical predictability, advancement of personalized medicine, and rise in the prevalence of cancer. However, ethical concerns surrounding the use of animal models are expected to restrain market growth to a certain extent.

The patient-derived xenografts/ PDX models market has been segmented based on type, implantation method, tumor type, application, end-user, and region.

“By type, the mouse model segment accounted for the largest share of the patient-derived xenografts/ PDX models market.”

Based on type, the patient-derived xenografts/ PDX models market is categorized into mouse model and rat model. The mouse model segment is the largest and fastest-growing segment in the market in 2023, owing to ease of manipulation and procurement, and the minimum requirement for keeping them under observation compared to rats in the facilities has led to a higher growth rate for products in the patient-derived xenografts/ PDX models market.

“By implantation method, subcutaneous implantation segment accounted for the largest share in the patient-derived xenografts/ PDX models market.”

Based on implantation method, the market is segmented into subcutaneous implantation, orthotopic implantation, and other implantation methods (heterotopic implantation, intraocular implantation, and under the renal capsule). In 2023, the subcutaneous segment accounted for the largest share and the fastest-growing segment of the patient-derived xenografts/ PDX models market. Subcutaneous implantation involves implanting patient-derived tumor tissue under the skin of a host animal (often a mouse). This method is relatively simple and minimally invasive compared to other implantation methods, making it a practical choice for researchers.

“North America: the largest share of the patient-derived xenografts/ PDX models market.”

North America accounted for the largest share of the patient-derived xenografts/ PDX models market. The region possesses a highly developed and robust biopharmaceutical industry, with advanced research and clinical infrastructure. This environment facilitates efficient collaboration between academia, research institutions, and pharmaceutical companies, enabling the effective utilization and adoption of PDX models.

Secondly, North America's regulatory framework supports the integration of innovative technologies, including PDX models, in preclinical and clinical research. The stringent regulatory standards ensure that PDX models are validated and applicable for drug development processes, thereby bolstering investor and industry confidence.

Moreover, the APAC region offers lucrative growth potential for the PDX models market. This region benefits from a robust healthcare infrastructure, a burgeoning biopharmaceutical industry, and a large patient population, fostering an ideal setting for PDX model utilization.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 63% and Demand Side- 37%

By Designation: Executives - 45%, Research Scientists- 30%, and Managers - 25%

By Country: North America- 40%, Europe- 25%, Asia Pacific- 20%, Latin America - 10%, and Middle East Africa- 5%

Prominent Players

JSR Corporation (Japan)

Wuxi Apptec (China)

The Jackson Laboratory (US)

Charles River Laboratories International, Inc. (US)

Taconic Biosciences, Inc. (US)

Oncodesign Precision Medicine (France)

Inotiv, Inc. (US)

Pharmatest Services (Finland)

Hera BioLabs (US)

EPO Berlin-Buch GmbH (Germany)

Xentech (France)

Urosphere (France)

Altogen Labs (US)

Abnova Corporation (US)

Genesis Biotechnology Group (US)

Biocytogen Pharmaceuticals Co., Ltd. (China)

Creative Animodel (US)

BioDuro-Sundia (US)

Aragen Life Sciences (India)

Shanghai LIDE Biotech Co., Ltd. (China)

Certis Oncology Solutions (US)

InnoSer (Netherlands)

IVRS AB (Sweden)

Beijing IDMO Co. Ltd. (China)

Shanghai Chempartner Co. Ltd. (China)

Research Coverage:

This report provides a detailed picture of the patient-derived xenografts/ PDX models market. It aims at estimating the size and future growth potential of the market across different segments, such as type, implantation method, tumor type, application, and end-user, and region (North America, Europe, Asia Pacific, Latin America, and Middle East Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall patient-derived xenografts/ PDX models market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (growing demand for personalized medicine, technological advancements in PDX technology, and rising investments for cancer research), restraints (FDA’s announcement to discontinue animal models for clinical trials), opportunities (emergence of CRISPR in biomedical research), and challenges (development of alternative animal testing methods) influencing the growth of the patient-derived xenografts/ PDX models market.

Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the patient-derived xenografts/ PDX models market.

Market Development: Comprehensive information about lucrative markets- the report analyses the patient-derived xenografts/ PDX models market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the patient-derived xenografts/ PDX models market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like JSR Corporation (Japan), The Jackson Laboratory (US), and Charles River Laboratories International, Inc. (US), among others, in the patient-derived xenografts/ PDX models market strategies. The report also helps stakeholders understand the pulse of the patient-derived xenografts/ PDX models market and provides them with information on key market drivers, restraints, challenges, and opportunities.


  • INTRODUCTION
    • STUDY OBJECTIVES
    • MARKET DEFINITION
    • INCLUSIONS AND EXCLUSIONS
    • STUDY SCOPE
      • MARKETS COVERED
      • YEARS CONSIDERED
      • CURRENCY CONSIDERED
    • LIMITATIONS
    • STAKEHOLDERS
    • SUMMARY OF CHANGES
    • RECESSION IMPACT
  • RESEARCH METHODOLOGY
    • RESEARCH DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • MARKET ESTIMATION METHODOLOGY
    • DATA TRIANGULATION METHODOLOGY
    • INDUSTRY INSIGHTS 2.5 RESEARCH ASSUMPTIONS
    • RECESSION IMPACT
      • Table GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (%)
      • Table US HEALTHCARE EXPENDITURE, 2019–2022 (USD MILLION)
      • Table US HEALTHCARE EXPENDITURE, 2023–2027 (USD MILLION)
  • EXECUTIVE SUMMARY
  • PREMIUM INSIGHTS
    • ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET
    • NORTH AMERICAN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER AND COUNTRY (2023)
    • PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION
  • MARKET OVERVIEW
    • INTRODUCTION
    • MARKET DYNAMICS
      • Table PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: IMPACT ANALYSIS
      • DRIVERS
      • RESTRAINTS
      • OPPORTUNITIES
      • CHALLENGES
    • TECHNOLOGY ANALYSIS
    • TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • SUPPLY CHAIN ANALYSIS
      • Table COMPANIES AND THEIR ROLE IN PATIENT-DERIVED XENOGRAFT (PDX) MODEL SUPPLY CHAIN
    • VALUE CHAIN ANALYSIS
    • ECOSYSTEM ANALYSIS
    • PORTER'S FIVE FORCES ANALYSIS
      • Table PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: PORTER'S FIVE FORCES ANALYSIS
      • INTENSITY OF COMPETITIVE RIVALRY
      • BARGAINING POWER OF SUPPLIERS
      • BARGAINING POWER OF BUYERS
      • THREAT OF SUBSTITUTES
      • THREAT OF NEW ENTRANTS
    • REGULATORY ANALYSIS
      • NORTH AMERICA
      • EUROPE
      • ASIA PACIFIC
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA
    • PRICING ANALYSIS
      • AVERAGE SELLING PRICE (ASP) OF PRODUCTS OFFERED BY THREE KEY PLAYERS, BY TYPE
        • Table AVERAGE SELLING PRICE (ASP) OF PRODUCTS OFFERED BY THREE KEY PLAYERS, BY TYPE (USD)
      • AVERAGE SELLING PRICE (ASP) TREND
    • PATENT ANALYSIS
    • KEY CONFERENCES AND EVENTS IN 2023
      • Table PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: KEY CONFERENCES AND EVENTS
    • KEY STAKEHOLDERS AND BUYING CRITERIA
      • KEY STAKEHOLDERS IN BUYING PROCESS
      • BUYING CRITERIA
  • PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD
    • INTRODUCTION
      • Table PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
    • SUBCUTANEOUS IMPLANTATION
      • FACILITATES REAL-TIME ASSESSMENT OF TUMOR GROWTH
        • Table SUBCUTANEOUS IMPLANTATION: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
        • Table SUBCUTANEOUS IMPLANTATION: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table SUBCUTANEOUS IMPLANTATION: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table SUBCUTANEOUS IMPLANTATION: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table SUBCUTANEOUS IMPLANTATION: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table SUBCUTANEOUS IMPLANTATION: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    • ORTHOTOPIC IMPLANTATION
      • PROVIDES HIGHLY ACCURATE REPRESENTATION OF TUMOR BEHAVIOR
        • Table ORTHOTOPIC IMPLANTATION: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
        • Table ORTHOTOPIC IMPLANTATION: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table ORTHOTOPIC IMPLANTATION: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table ORTHOTOPIC IMPLANTATION: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table ORTHOTOPIC IMPLANTATION: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table ORTHOTOPIC IMPLANTATION: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    • OTHERS
      • Table OTHERS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
      • Table OTHERS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
      • Table OTHERS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
      • Table OTHERS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
      • Table OTHERS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
      • Table OTHERS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE
    • INTRODUCTION
      • Table PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
    • MOUSE MODEL
      • GROWING USE IN CANCER RESEARCH AND DRUG DEVELOPMENT
        • Table MOUSE MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
        • Table MOUSE MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table MOUSE MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table MOUSE MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table MOUSE MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table MOUSE MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    • RAT MODEL
      • DEVELOPMENT OF NEW TECHNOLOGIES TO CREATE PDX RAT MODELS AT FASTER RATE
        • Table RAT MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
        • Table RAT MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table RAT MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table RAT MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table RAT MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table RAT MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION
    • INTRODUCTION
      • Table PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
    • PRECLINICAL DRUG DEVELOPMENT
      • INCREASED NUMBER OF CLINICAL TRIALS
        • Table PRECLINICAL DRUG DEVELOPMENT: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
        • Table PRECLINICAL DRUG DEVELOPMENT: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table PRECLINICAL DRUG DEVELOPMENT: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table PRECLINICAL DRUG DEVELOPMENT: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table PRECLINICAL DRUG DEVELOPMENT: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table PRECLINICAL DRUG DEVELOPMENT: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    • BIOMARKER ANALYSIS
      • GROWING DEMAND FOR BIOMARKER-BASED PERSONALIZED CANCER THERAPY
        • Table BIOMARKER ANALYSIS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
        • Table BIOMARKER ANALYSIS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table BIOMARKER ANALYSIS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table BIOMARKER ANALYSIS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table BIOMARKER ANALYSIS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table BIOMARKER ANALYSIS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    • TRANSLATIONAL RESEARCH
      • BOOMING PERSONALIZED MEDICINE MARKET
        • Table TRANSLATIONAL RESEARCH: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
        • Table TRANSLATIONAL RESEARCH: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table TRANSLATIONAL RESEARCH: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table TRANSLATIONAL RESEARCH: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table TRANSLATIONAL RESEARCH: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table TRANSLATIONAL RESEARCH: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    • BIOBANKS
      • RISING DRUG DISCOVERY AND DEVELOPMENT PROJECTS
        • Table BIOBANKS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
        • Table BIOBANKS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table BIOBANKS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table BIOBANKS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table BIOBANKS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table BIOBANKS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER
    • INTRODUCTION
      • Table PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
    • PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
      • ADVANCEMENTS IN TUMOR MICROENVIRONMENT RESEARCH
        • Table PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
        • Table PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, 2021–2028 (USD MILLION)
        • Table PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: MIDDLE EAST & AFRICA PATIENTDERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    • CONTRACT RESEARCH ORGANIZATIONS (CROS)
      • INCREASING OUTSOURCING OF DRUG DISCOVERY SERVICES
        • Table CONTRACT RESEARCH ORGANIZATIONS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
        • Table CONTRACT RESEARCH ORGANIZATIONS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table CONTRACT RESEARCH ORGANIZATIONS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table CONTRACT RESEARCH ORGANIZATIONS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table CONTRACT RESEARCH ORGANIZATIONS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table CONTRACT RESEARCH ORGANIZATIONS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    • ACADEMIC & RESEARCH INSTITUTIONS
      • RISING R&D INVESTMENTS IN LIFE SCIENCES
        • Table ACADEMIC & RESEARCH INSTITUTIONS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
        • Table ACADEMIC & RESEARCH INSTITUTIONS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table ACADEMIC & RESEARCH INSTITUTIONS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table ACADEMIC & RESEARCH INSTITUTIONS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table ACADEMIC & RESEARCH INSTITUTIONS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table ACADEMIC & RESEARCH INSTITUTIONS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE
    • INTRODUCTION
      • Table PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
    • GASTROINTESTINAL TUMOR MODEL
      • RISING DEMAND FOR EFFECTIVE CANCER THERAPEUTICS
        • Table GASTROINTESTINAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
        • Table GASTROINTESTINAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table GASTROINTESTINAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table GASTROINTESTINAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table GASTROINTESTINAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table GASTROINTESTINAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    • GYNECOLOGICAL TUMOR MODEL
      • HIGH INCIDENCE OF TARGET CANCERS
        • Table GYNECOLOGICAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
        • Table GYNECOLOGICAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table GYNECOLOGICAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table GYNECOLOGICAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table GYNECOLOGICAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table GYNECOLOGICAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    • RESPIRATORY TUMOR MODEL
      • INCREASING PREVALENCE OF LUNG CANCER
        • Table RESPIRATORY TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
        • Table RESPIRATORY TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table RESPIRATORY TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table RESPIRATORY TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table RESPIRATORY TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table RESPIRATORY TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    • UROLOGICAL TUMOR MODEL
      • INCREASING FOCUS OF COMPANIES ON EXPANDING PORTFOLIO OF UROLOGICAL TUMOR MODELS
        • Table UROLOGICAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
        • Table UROLOGICAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table UROLOGICAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table UROLOGICAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table UROLOGICAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table UROLOGICAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    • HEMATOLOGICAL TUMOR MODEL
      • ADVANCEMENTS IN TRANSLATIONAL RESEARCH AND INCREASING DEMAND FOR PERSONALIZED MEDICINE
        • Table HEMATOLOGICAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
        • Table HEMATOLOGICAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table HEMATOLOGICAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table HEMATOLOGICAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table HEMATOLOGICAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
        • Table HEMATOLOGICAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    • OTHERS
      • Table OTHERS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
      • Table OTHERS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
      • Table OTHERS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
      • Table OTHERS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
      • Table OTHERS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
      • Table OTHERS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION
    • INTRODUCTION
      • Table PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
    • NORTH AMERICA
      • Table NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
      • Table NORTH AMERICA: PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
      • Table NORTH AMERICA: PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
      • Table NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
      • Table NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
      • Table NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • US
        • Table US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • CANADA
        • Table CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • NORTH AMERICA: IMPACT OF RECESSION
    • EUROPE
      • Table EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
      • Table EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
      • Table EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
      • Table EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
      • Table EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
      • Table EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • GERMANY
        • Table GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • FRANCE
        • Table FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • UK
        • Table UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • ITALY
        • Table ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • SPAIN
        • Table SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • REST OF EUROPE
        • Table REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • EUROPE: IMPACT OF RECESSION
    • ASIA PACIFIC
      • Table ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
      • Table ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
      • Table ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
      • Table ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
      • Table ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
      • Table ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • CHINA
        • Table CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • JAPAN
        • Table JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • INDIA
        • Table INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • SOUTH KOREA
        • Table SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • AUSTRALIA
        • Table AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • REST OF ASIA PACIFIC
        • Table REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • ASIA PACIFIC: IMPACT OF RECESSION
    • LATIN AMERICA
      • Table LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
      • Table LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
      • Table LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
      • Table LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
      • Table LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
      • Table LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • BRAZIL
        • Table BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • REST OF LATIN AMERICA
        • Table REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • LATIN AMERICA: IMPACT OF RECESSION
    • MIDDLE EAST & AFRICA
      • Table MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
      • Table MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
      • Table MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
      • Table MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
      • Table MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
      • Table MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • MIDDLE EAST
        • Table MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
      • AFRICA
        • Table AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
        • Table AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
        • Table AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
        • Table AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
        • Table AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021– 2028 (USD MILLION)
      • MIDDLE EAST & AFRICA: IMPACT OF RECESSION
  • COMPETITIVE LANDSCAPE
    • OVERVIEW
    • KEY STRATEGIES ADOPTED BY MAJOR PLAYERS
    • REVENUE SHARE ANALYSIS OF TOP FOUR PLAYERS, 2022
    • MARKET SHARE ANALYSIS OF TOP FOUR PLAYERS, 2020–2022
    • COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
      • STARS
      • EMERGING LEADERS
      • PERVASIVE PLAYERS
      • PARTICIPANTS
    • COMPANY EVALUATION MATRIX FOR STARTUPS/SMALL AND MEDIUM-SIZED ENTERPRISES (SMES), 2022
      • PROGRESSIVE COMPANIES
      • STARTING BLOCKS
      • RESPONSIVE COMPANIES
      • DYNAMIC COMPANIES
    • COMPETITIVE BENCHMARKING
      • PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: LIST OF STARTUPS/SMES
        • Table PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: LIST OF STARTUPS/SMES
      • PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
        • Table PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
    • COMPETITIVE SCENARIOS AND TRENDS
      • DEALS
        • Table PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: DEALS, 2021–2023
      • OTHERS
        • Table PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: OTHERS, 2021–2023
  • COMPANY PROFILES
    • KEY PLAYERS
      • JSR CORPORATION
        • Table JSR CORPORATION: COMPANY OVERVIEW
      • WUXI APPTEC
        • Table WUXI APPTEC: COMPANY OVERVIEW
      • THE JACKSON LABORATORY
        • Table THE JACKSON LABORATORY: COMPANY OVERVIEW
      • CHARLES RIVER LABORATORIES
        • Table CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
      • TACONIC BIOSCIENCES, INC.
        • Table TACONIC BIOSCIENCES, INC.: COMPANY OVERVIEW
      • ONCODESIGN PRECISION MEDICINE
        • Table ONCODESIGN PRECISION MEDICINE: COMPANY OVERVIEW
      • INOTIV, INC.
        • Table INOTIV, INC.: COMPANY OVERVIEW
      • PHARMATEST SERVICES
        • Table PHARMATEST SERVICES: COMPANY OVERVIEW
      • HERA BIOLABS
        • Table HERA BIOLABS: COMPANY OVERVIEW
      • EPO BERLIN-BUCH GMBH
        • Table EPO BERLIN-BUCH GMBH: COMPANY OVERVIEW
      • XENTECH
        • Table XENTECH: COMPANY OVERVIEW
      • UROSPHERE
        • Table UROSPHERE: COMPANY OVERVIEW
      • ALTOGEN LABS
        • Table ALTOGEN LABS: COMPANY OVERVIEW
      • ABNOVA CORPORATION
        • Table ABNOVA CORPORATION: COMPANY OVERVIEW
      • GENESIS BIOTECHNOLOGY GROUP
        • Table GENESIS BIOTECHNOLOGY GROUP: COMPANY OVERVIEW
    • OTHER PLAYERS
      • BIOCYTOGEN PHARMACEUTICALS CO., LTD.
      • CREATIVE ANIMODEL
      • BIODURO-SUNDIA INC.
      • ARAGEN LIFE SCIENCES
      • SHANGHAI LIDE BIOTECH CO., LTD.
      • CERTIS ONCOLOGY SOLUTIONS
      • INNOSER
      • IVRS AB
      • BEIJING IDMO CO. LTD.
      • SHANGHAI CHEM PARTNER CO. LTD.
  • APPENDIX
    • KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
    • CUSTOMIZATION OPTIONS
    • RELATED REPORTS
    • AUTHOR DETAILS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings